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Background: The insulin analogs, glargine and detemir, are associated with reduced 
hypoglycemia incidence compared with NPH insulin. We assessed the impact of changing 
basal insulin from NPH to glargine or detemir in patients with type 1 diabetes mellitus who 
experienced severe hypoglycemia.
Material and methods: A retrospective chart review was conducted that included 
73 (31 female) patients (mean age 48 years, diabetes duration 19 years) treated for 12 to 
24 months with insulin glargine (n = 43) or detemir (n = 30).
Results: There were no patients who withdrew from treatment due to side effects. The mean 
treatment duration in both groups was 18 months. Changing from NPH insulin was associated 
with a −0.3% (p = 0.036) reduction in HbA1c for glargine (baseline 8.8%) and −0.4% (p = 0.040) 
for detemir (baseline 8.3%) treated patients; insulin dosages increased, respectively by 
4.1 (p = 0.045) and 4.3 units (p = 0.004) (mean values). Weight did not increase signiﬁ  cantly 
and the 1-year rate of serious hypoglycemia was 0.25/person/year.
Conclusion: Switching from NPH-insulin to insulin detemir or glargine in type 1 diabetes 
mellitus patients with previous serious hypoglycemia was associated with a reduction in HbA1c. 
However, severe hypoglycemia was not completely eliminated, and few patients reached 
internationally accepted glycemic treatment goals.
Literature search: We searched Medline, PubMed (with key search terms type 1 diabetes, 
NPH insulin, detemir, glargine and serious hypoglycemia), reference lists and databases of 
ongoing and completed trials (through July 2008) provided from the manufacturers of the drugs 
to identify relevant literature.
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Introduction
Neutral protamine Hagedorn (NPH) insulin is the most widely used basal insulin 
worldwide.1 However, NPH insulin may not be the optimal basal insulin due to 
its signiﬁ  cant day-to-day variability, bell-shaped effect curve and estimated 12- to 
15-hour duration of action.2,3 In addition, being a suspension of crystals, it needs proper 
re-suspension, a fact that is often disregarded by patients.4 These characteristics of 
NPH-insulin render patients more prone to hypoglycemia and usually require the users 
to be on a twice daily injection schedule to attain 24-hour basal insulin coverage.3 NPH 
insulin is also associated with weight gain,5 thus further reducing potential compliance.6 
These are all factors that are barriers for achieving good glycemic control.
These shortcomings of NPH insulin spurred the development of other basal insulin 
formulations, of which two are currently marketed: insulin glargine (Lantus®; Sanoﬁ   
Aventis, France); and insulin detemir (Levemir®; Novo Nordisk, Denmark). Glargine is 
synthesized via the substitution of glycine for asparagine at position A21 of the insulin 
molecule and the addition of two arginine molecules at position B30;2,7 detemir is Vascular Health and Risk Management 2009:5 122
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acylated with a fatty-acid chain (myristic acid) to the lysine at 
residue B29 of the insulin molecule which mediates albumin 
binding in the interstitial ﬂ  uid and plasma.2,8,9 Both come in 
a clear solution and do not require re-suspension.
Although none of the basal insulin analogs have a 
completely “ﬂ  at” pharmacokinetic proﬁ  le,3 the modula-
tions of the human insulin molecule inherent in detemir 
and glargine contribute to a “ﬂ  atter” and more protracted 
pharmacodynamic proﬁ  le, with signiﬁ  cantly lower within-
subject variability, compared with NPH insulin.2,10 In ran-
domized controlled trials (RCT) comparing these insulin 
analogs with NPH insulin, insulin glargine and detemir 
demonstrated similar reductions in HbA1c and fasting 
plasma glucose compared to NPH insulin. Further, the use 
of these long-acting analogs has also been associated with 
fewer hypoglycemic episodes, particularly nocturnal hypo-
glycemia, and has also been associated with less weight gain 
(especially for detemir) than NPH insulin.5,11,12,13,14
For these reasons, governmental authorities and/or other 
payers (eg, insurance companies) in several industrialized 
countries around the globe (eg, Sweden, Finland, Denmark, 
UK, US, Australia, Canada, Germany, Spain, France, 
South Africa) have granted general reimbursement for detemir 
and glargine in type 1 diabetes mellitus (T1DM), and in some 
regions their use has exceeded that of  NPH insulin. In Norway 
however, this is currently not the case. The ﬁ  nal decision 
for whether a medicine in Norway will be added to the drug 
reimbursement formulary lies with the parliament. However, 
the Norwegian Medicines Agency has the authority to grant 
reimbursement without consent of the Parliament if the esti-
mated annual increase in cost for national insurance is less than 
NOK5 million (approximately US$0.8 million) for the 5 years 
following the approval of such reimbursement.15
The Parliament bases their decision on advice from the 
Norwegian Medicines Agency and the Ministry of Health 
and Social Affairs who evaluate all applications regarding 
medical and health economic issues. There are four possible 
outcome of this process: reimbursement denied (as is the 
case for orlistat); full reimbursement (as is the case for 
NPH insulin and all short acting insulin analogs); restricted 
reimbursement (limited to a certain numbers of prescriptions 
per year as is currently is the case for the glitazones),15 and 
reimbursement on a named basis, which means individual 
patient application for reimbursement and evaluation is on 
a case by case basis.18 The latter option currently prevails in 
Norway for the long-acting insulin analogs. However, the 
likelihood for a patient to obtain this product reimbursed is 
restricted since the application must come from a specialist in 
internal medicine or paediatrics. Additionally, it is required 
that NPH insulin has previously has been tried and that the 
patient experienced either frequent, or serious nocturnal, 
hypoglycemic episode(s) or blood glucose variations to an 
extent that limits optimal glycemic control.17 Patients in 
Norway with T1DM who receive long-acting insulin analogs 
by the reimbursement system must therefore be more difﬁ  cult 
to manage than patients included in other studies; whether 
previous RCT results also are applicable to this patient 
group remains uncertain. We therefore decided to undertake 
evaluation of the long-term impact on HbA1c in patients 
with T1DM and at least one documented episode of serious 
hypoglycemia whose basal insulin prescription was changed 
from NPH to detemir or glargine. Secondarily, we evaluated 
the impact of such a change in basal insulin on weight gain, 
insulin dosage and administration, drug side effects and the 
frequency of serious hypoglycemic episodes.
Materials and methods
Inclusion criteria and data collection
This retrospective chart review was performed at the 
diabetic outpatient clinic at Asker and Baerum Hospital 
(a secondary referral centre in eastern Norway that serves 
150,000 residents), where approximately 800 patients with 
DM receive regular follow-up. Care of T1DM patients is 
facilitated by a physician or diabetes nurse specialist visit at 
either 3- or 6-month intervals; these visits include assessment 
of body weight, HbA1c, lipids, plasma glucose, hemoglobin, 
creatinine, and insulin regimen (dosage, time and numbers 
of injections). In addition episodes of serious hypoglycemia 
(deﬁ  ned as an event requiring assistance of another person to 
actively administer carbohydrate, glucagon, or other resus-
citative actions)18 are recorded. Patients are referred to an 
ophthalmologist on a yearly basis and urine albumin excre-
tion rate is evaluated annually. Patients are typically advised 
to regulate their bolus insulin dosages as needed according 
to meal composition and inﬂ  uence of any physical activity, 
alcohol consumption or other factors known to effect insulin 
needs; the goal is to maintain 2-hour postprandial, fasting 
and bedtime glucose levels in the range of 4 to 8 mmol/L 
(72–144 mg/dL). If these goals are not achieved, we recom-
mend that evening, or morning (or both), basal insulin doses 
are titrated in steps of 2 units (every third day), until respec-
tive blood glucose levels are within target range.
Inclusion criteria in this retrospective chart review were: 
age   18 years; T1DM; regular use of insulin glargine or 
detemir prescription for 12 to 24 months between Dec 2003 
and Dec 2007; history of episodes of severe hypoglycemia as Vascular Health and Risk Management 2009:5 123
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per the deﬁ  nition noted above. Exclusion criteria were prior 
basal insulin use other than NPH-insulin and T2DM.
Subjects eligible for inclusion were identiﬁ  ed by authors 
and personnel at the outpatient clinic. Data from the charts 
were consistently collected by two persons (authors, OEJ 
and PJV) and data analysis was conducted by OEJ so as to 
minimize bias. Results were interpreted after consultation 
among all authors.
Collection and analysis of blood samples
Venous blood samples are drawn between 8 and 10 AM after 
an overnight fast, within 7 days prior to outpatient clinic visits 
and are analyzed within 24 hours at the central laboratory of 
the hospital. Plasma glucose is analysed by utilization of the 
glucose hexokinase method and HbA1c (upper normal refer-
ence value of 6.2%) is analyzed utilizing colorimetric and 
immunoturbidimetrical methods (Cobas Integra, Roche Diag-
nostics GmbH, Mannheim, Germany). Serum levels of total 
cholesterol, high-density lipoprotein (HDL)-cholesterol and 
triglycerides (TG) are measured enzymatically on a Roche/
Hitachi 917 analyzer (Roche Diagnostics GmbH, Mannheim, 
Germany) whereas low-density lipoprotein (LDL) cholesterol 
is calculated using the Friedewald formula.
Statistical analysis
Based on 2 studies with similar design (a Finnish switch 
study reporting data for 62 subjects treated for 12 months 
and a Japanese switch study reporting data for 72 subjects 
treated for 18 months) we estimated that we in total needed 
a minimum of 72 subjects treated for a minimum of 12, and 
a maximum of 24, months with either insulin glargine or 
insulin detemir19,20 in order to evaluate the long term impact 
of basal insulin switch according to HbA1c results.
Data analysis was performed using SPSS statistical 
software version 14.0.1 for Windows (SPSS Inc.). Results 
for continuous variables are presented as mean and standard 
deviation unless otherwise stated and categorical variables 
are presented as counts or proportions (%). Since there was 
no randomization in this survey we did not perform any 
between-group comparisons. Comparisons for continuous 
data were performed with a paired t-test and Pearson bivariate 
correlation. Comparisons between categorical variables were 
carried out by chi-squared or Fisher exact test. P-values are 
2-sided and considered signiﬁ  cant when  0.05.
Results
In total, 98 patients with DM were found to have used a 
long-acting insulin analog in the deﬁ  ned period (31.12.2003 to 
31.12.2007). Among these, 9 had type 2 DM, 7 were missing 
initiation data, 1 person used a non-NPH based basal insulin 
(insulin pump) and 8 had been prescribed insulin analog 
treatment for a period of less than 12 months. Hence, in total, 
73 patients were eligible for analysis, 43 who received a pre-
scription for insulin glargine and 30 for insulin detemir.
The mean follow-up period from initiation of detemir or 
glargine treatment to last observation was 18 ± 6 (minimum 12, 
maximum 24) months in both groups. Generally, the patients 
who had been prescribed these insulins were characterized 
by relatively long diabetes duration (18 years) and had a 
relatively high prevalence of micro- and macro-vascular 
complications (Table 1).
Table 2 shows the insulin regimens that were used at the 
time of switching to a long-acting insulin analog. Ninety-three 
percent of subjects used NPH insulin in a twice-daily regimen, 
99% had at least one injected dose of bolus insulin whereas 
58% injected bolus insulin  4 times per day (ie, breakfast, 
lunch, dinner, evening meal as well as with snacks).
The change to detemir was associated with a statisti-
cally significant, −0.4% (95% confidence interval [CI] 
(−0.7, −0.1), p = 0.04), reduction in HbA1c among subjects 
(baseline 8.3%) and the change to glargine was associated 
with a −0.3% (95% CI (−0.6, −0.1), p = 0.036) reduction 
(baseline 8.8%) (Figure 1a). However, the switch did not 
increase the proportion of patients with HbA1c   7.0% (ie, 
3 and 5 patients before switching to glargine or detemir and, 
respectively, 4 and 6 after 1 year).
Table 3 details the half-yearly changes in long-acting 
and bolus insulin dosages, as well as changes in HbA1c, 
throughout 24 months. All patients using glargine started with 
a once-daily regimen (32 [74%] in the evening); however, 
after 24 months, 33% used a twice-daily regimen. Corre-
spondingly, 20% of the detemir users initiated usage with 
once-daily regimen, but after 24 months, all were following 
a twice-daily regimen.
Mean insulin detemir and glargine dosages increased, 
respectively by 4.3 units (U) (95% CI (1.5, 7.1), p = 0.004) 
and 4.1 U (95% CI (0.1, 8.1), p = 0.045), while the bolus 
insulin dosage did not (Figure 1b). Weight increased, but 
not in a statistically signiﬁ  cant manner, in both groups 
(Figure 1a): 0.8 (95% CI (−1.7, 3.3), p = 0.515) kg in the 
glargine- and 0.3 kg (95% CI (−3.4, 4.0), p = 0.877) in the 
detemir-treated group.
No correlations were noted between baseline weight 
and changes in HbA1c, or between baseline weight and 
changes in weight. However, a signiﬁ  cant negative correla-
tion was seen between baseline HbA1c and the reduction Vascular Health and Risk Management 2009:5 124
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in HbA1c for both detemir (r = −0.657, p   0.001) and 
glargine (r = −0.507, p = 0.001). There was also a signiﬁ  cant 
correlation between the increase in insulin dose and reduc-
tion in HbA1c for detemir (r = 0.439, p = 0.025), but not for 
glargine (r = 0.236, p = 0.160).
During the ﬁ  rst 12 months, 15 patients experienced a 
total of 18 serious hypoglycemic episodes, which translates 
to 0.25 episodes/person year during treatment and such 
occurrences were similarly distributed among the two 
groups.
One patient was hospitalized due to ketoacidosis after 6 
months of detemir treatment and 2 non-hypoglycemic side 
effects were observed. One patient developed edema and 
joint achiness immediately after the initiation of glargine, and 
Table 1 Background data and glycemic and lipid parameters (before changing basal insulin analogs) for 73 patients with T1DM treated 
with a long-acting insulin analog (detemir or glargine) for 12 to 24 months
All 
(n = 73)
Detemir 
(n = 30)
Glargine 
(n = 43)
Background
  Age (year) 48 (17,83) 52 (23,78) 46 (17,83)
  Gender (male/female) 42 (58%)/
31 (42%)
16 (53%)/
14 (47%)
26 (61%)/
17 (39%)
  Diabetes duration (year) 19 (1,54) 26 (1,54) 14 (2, 45)
  Weight (kg) 78.3 (49.4, 131.0) 81.4 (51.0, 131.0) 76.4 (49.4, 105.0)
 BMI  (kg/m2) 25.9 (16.9, 42.8) 27.2 (22.9, 42.8) 25.3 (16.9, 33.0)
Microvascular complications
  Retinopathy 25 (34%) 16 (53%) 9 (21%)
  Neuropathy 16 (22%) 8 (27%) 8 (19%)
  Albuminuria (micro/macro) 24 (33%) 11 (37%) 13 (30%)
Other complications
   Cerebro, peripheral or 
coronary artery disease
27 (37%) 15 (50%) 12 (28%)
  Thyroid disorder 9 (12%) 3 (10%) 6 (14%)
Medications other than insulin
  Statins 32 (44%) 18 (60%) 14 (33%)
  Platelet inhibitor 17 (23%) 9 (30%) 8 (19%)
   ACE-inhibitor/ AT-II receptor 
blocker
31 (44%) 17 (57%) 14 (33%)
  Diuretics 13 (18%) 6 (20%) 7 (16%)
Laboratory parameters
  HbA1c (%) 8.6 (5.7, 11.7) 8.3 (5.7, 11.3) 8.8 (6.8, 11.7)
  Glucose mmol/L 11.6 (2.4, 24.0) 10.7 (2.4, 18.5) 12.2 (3.2, 24.0)
mg/dL 208.8 (43.2, 432.0) 192.6 (43.2, 333.0) 219.6 (57.6, 432.0)
   Total 
cholesterol
mmol/L 4.8 (3.0, 7.6) 4.9 (3.6, 6.3) 4.8 (3.0, 7.6)
mg/dL 186 (116, 294) 189 (139, 244) 186 (116, 294)
   LDL-
cholesterol
mmol/L 2.6 (1.1, 4.4) 2.5 (1.2, 3.5) 2.6 (1.1, 4.4)
mg/dL 101 (43, 170) 97 (46, 135) 101 (43, 170)
   HDL-
cholesterol
mmol/L 1.7 (0.9, 2.9) 1.9 (1.2, 2.9) 1.6 (0.9, 2.8)
mg/dL 66 (35, 112) 73 (46, 112) 62 (35, 112)
Triglycerides mmol/L 1.1 (0.4, 2.7) 0.9 (0.4, 2.1) 1.2 (0.4, 2.7)
mg/dL 97 (35, 239) 78 (35, 186) 106 (35, 239)
Hemoglobin (g/dL) 14.1 (10.8, 16.3) 14.2 (11.0, 16.3) 14.0 (10.8, 16.2)
Creatinine (μmol/L) 76 (41, 153) 75 (44, 118) 77 (41, 153)
Note: Data given as mean (min., max.) for numerical and n (%) for categorical parameters.
Abbreviations: ACE, angiotensin converting enzyme; AT-II, angiotensin II; HbA1c, hemoglobin A1c; LDL, low density lipoprotein; HDL, high density lipoprotein.Vascular Health and Risk Management 2009:5 125
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1 developed a local injection site reaction after 21 months 
of treatment on detemir. None of these events necessitated 
treatment withdrawal.
Discussion
This retrospective chart review on the use of long-acting 
insulin analogs over a period of 12 to 24 months in 73 patients 
with T1DM who had had at least 1 documented episode of 
serious hypoglycemia, demonstrates that changing from NPH 
insulin to detemir or glargine improved glycemic control with 
corresponding decreases in HbA1c levels of −0.3% to 0.4%. 
The fact that HbA1c levels were not even more dramatically 
improved may be related to lack of application of a strict treat-
to-target algorithm, as in contrast to those in the RCT,13,14 and 
that the T1DM patients included in this analysis probably 
are not representative for all patients with T1DM (ie, due to 
the inclusion criterion), hence their diabetes is possibly more 
difﬁ  cult to manage. Predictors for HbA1c improvements were 
high HbA1c and a positive insulin dosage titration. Interest-
ingly, similar levels of HbA1c reduction was achieved with 
similar increases in insulin dose for both insulin analogs, 
which is at variance with some head-to-head RCTs where 
higher detemir dosages were needed.21,22 There was also 
the statistically insigniﬁ  cant correlation between HbA1c 
reduction and weight increase, which is a well-established 
side effect of NPH-insulin,5 although this ﬁ  nding must be 
cautiously interpreted.
The impact of these insulin analogs on glycemic control 
in the current study population is consistent with results 
from other observational studies documenting a change from 
NPH to other basal insulins,19,22,23 although conﬂ  icting data 
also exist. One recent publication reports that 62 adolescents 
treated with glargine for 12 months in Finland had no change 
in HbA1c (ie, 9.2% both at initiation and 12 months).20 
A similar conclusion was recently drawn in a Cochrane review 
article where no glycemic beneﬁ  t of long-acting insulin ana-
logs was found compared with intermediate-acting insulin,24 
although a beneﬁ  cial effect on both nocturnal and severe 
hypoglycemia was noted, with odds ratios of respectively 0.70 
(95% CI 0.63–0.79) and 0.73 (95% CI 0.61–0.87). However, 
it should be noted that this report included studies of relatively 
short duration, and it is unknown if conclusions would change 
if studies of longer duration were included.
Serious hypoglycemia was not eliminated after the 
change from NPH insulin to the detemir or glargine, and still 
occurred at a prevalence of 0.25/person year of treatment. 
In a 9- to 12-month long observational study in the UK, the 
corresponding rate of serious hypoglycemia among patients 
with T1DM (mean HbA1c 7.8%, diabetes duration 30 years) 
was 3.2.25 Hence the hypoglycemia rate seen seems low in 
our survey and is in line with the ﬁ  ndings from the Cochrane 
review,24 but this variance could be related to uncertainties 
or discrepancies in collection and reporting procedures, 
in addition to differences in patient characteristics and 
Table 2 Details of insulin treatment regimens prior to changing basal insulin from NPH to detemir or glargine
  All (n = 73) Detemir (n = 30) Glargine (n = 43)
Basal insulin (NPH)
Daily insulin dosage (U) 30 (10, 80) 28 (10, 74) 31 (12, 80)
  Number of injections (n)
    1 5 (7%) 3 (10%) 2 (5%)
    2 68 (93%) 27 (90%) 41 (95%)
Bolus insulin
  Human insulin (n) 7 (10%) 2 (7%) 5 (12%)
  Insulin analog (n) 65 (89%) 28 (93%) 37 (86%)
  No bolus insulin (n) 1 (1%) 0 (0%) 1 (2%)
  Daily insulin dosage (U) 24 (0, 80) 25 (10, 80) 24 (0, 72)
  Number of injections (n)
    0 1 (1%) 0 (0%) 1 (2%)
    1 4 (6%) 1 (3,3%) 3 (7%)
  2 6  (8%) 2  (6,7%) 4  (9%)
    3 20 (27%) 6 (20%) 14 (33%)
   4 42 (58%) 21 (70%) 21 (49%)
Note: Data given as mean (min., max.) for numerical and n (%) for categorical parameters.
Abbreviation: U, international unit.Vascular Health and Risk Management 2009:5 126
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hypoglycemia occurrence rate as we did not register this 
rate prior to the switch.
Of interest is also that one third of the patients treated with 
glargine throughout the 2-year period used it twice daily. This 
is at variance with the Summary of Product Characteristics 
(SmPC), stating that glargine should be administrated once 
daily, while detemir can be administered once or twice daily. 
This ﬁ  nding is, however, supported by other reports indicat-
ing that glargine twice daily is in fact needed in 25% to 33% 
of adult patients with T1DM.26,27,28
In conclusion, although the proportion of patients who 
attained optimal glycemic control (ie,  7.0% by HbA1c) 
was low, serious hypoglycemic episodes were not completely 
eliminated, the current analyses are limited by being retrospec-
tive, are not corrected for the impact of possible confounding 
factors and were conducted on a limited number of patients, 
we believe that a 0.3% to 0.4% reduction in HbA1c, and 
results indicating a relatively low 1-year rate of serious 
hypoglycemia, are of clinical interest. The improvements 
noted are important, not only due to the preventive effect on 
micro- and macrovascular complications,29 but more so in 
improving quality of life.24,30 On the other hand, this study also 
underscores the fact that long-acting insulin analogs alone do 
not solve the problem related to achieving optimal glycemic 
control and additional tools are needed for the treatment 
armamentarium for this particular group of patients.
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